SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses potential catalysts including upcoming news, partnerships, and the possibility of a major exchange listing. Bullish sentiment is fueled by comparisons to early XRP and anticipation of the Zebec Super App launch. Many believe ZBCN is positioned for significant growth and real-world adoption within the evolving financial landscape.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid community debate about its technology and future prospects, with some users expressing skepticism about eVTOL capabilities and range limitations. Bullish investors are pointing to upcoming events like the California International Air Show and potential military contracts as catalysts for growth. A possible collaboration with Tesla has also surfaced as a point of discussion among investors.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is trending amid community excitement around its cross-chain automation capabilities and the upcoming sunsetting of $PRQ, which some believe has been suppressing its price. The community is also anticipating new exchange listings and marketing campaigns, while highlighting its strong technology and staking rewards. Discussions include potential price targets and the belief that $REACT is an undervalued gem with significant long-term potential.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto, CAW, is trending due to community enthusiasm around its meme-based identity, "crow with knife," and its expansion across multiple chains. Community members highlight its strong community and deflationary aspects, with many urging others to add it to their watchlist. Bullish sentiment and repetitive "caw caw" messaging dominate the conversation.

Roundhill ETF Trust - Roundhill WeeklyPay Universe ETF

Roundhill WeeklyPay™ Universe ETF

The Roundhill WeeklyPay™ Universe ETF ($WPAY) is trending as investors discuss its weekly dividend payouts and compare it to other high-yield ETFs. Community members are actively sharing dividend amounts and payout schedules, while also debating its valuation and potential for NAV erosion. Some are rotating into $WPAY from other dividend plays, drawn to its promise of consistent income.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as investors debate its valuation amid a broader surge in quantum computing stocks; the community is split between those touting long-term potential and others pointing to financial losses and share dilution. Discussions also involve comparing RGTI's metrics and facilities to both established tech companies and other quantum computing firms. Some traders are closely watching for potential pullbacks or offering announcements.

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Glaukos Corporation

Glaukos ($GKOS) is trending due to positive Phase 3 trial results for its iDose TR glaucoma treatment, which met primary efficacy endpoints and showed a favorable safety profile. The community is actively discussing the potential for this innovative drug delivery system to disrupt the glaucoma treatment market. Analysts are updating ratings and price targets, reflecting optimism about Glaukos's pipeline and market position in ophthalmic therapies.

Leidos Holdings, Inc. engages in providing services and solutions in the defense, intelligence, civil and health markets. It operates through the following three segments: Defense Solutions, Civil, and Health. The Defense Solutions segment provides services, solutions, and products focusing on digital modernization, mission systems and integration, command, control, computers, communications, intelligence, surveillance and reconnaissance technologies and services, maritime solutions, transformative software, analytics, intelligence analysis, mission support and logistics services, weapons systems and space systems and solutions. The Civil segment focuses on modernizing infrastructure, systems, and security. The Health segment offers solutions to federal and commercial customers that are responsible for the health and wellbeing of people worldwide including service members and veterans. The company was founded by John Robert Beyster on February 3, 1969 and is headquartered in Reston, VA.

Leidos Holdings Inc

Leidos is trending due to unusual options activity and positive sentiment around its government IT services and AI integration, with community members highlighting institutional accumulation and potential for growth. Increased call option volume suggests bullish expectations, while some analysts have raised price targets, citing strength in federal digital and health services. Community members are also discussing defense budget tailwinds and contract backlog visibility as positive catalysts for the stock.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF ($BTC) is trending as traders discuss the potential impact of Bitcoin's price movements on the fund. Community members are analyzing option volume and technical charts, with some anticipating a rally towards new all-time highs for Bitcoin and related assets.

Investment Managers Series Trust II - Tradr 2X Long UPST Daily ETF

Tradr 2X Long UPST Daily ETF

Traders are actively discussing $UPSX, a 2x leveraged ETF for Upstart, with many highlighting it as a way to amplify potential gains from $UPST, especially amid anticipation of future rate cuts. The community is weighing the risks and rewards of using the ETF, with some expressing concerns about its correlation to the underlying stock and others seeing it as a potential high-reward play. Overall sentiment leans bullish, with some expecting a significant move if $UPST rebounds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program

Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.

U.S. equities declined in Wednesday’s afternoon trade as investors cautiously await the release of key economic data this week, including the third estimate of gross domestic product (GDP) for the second quarter (Q2) on Thursday, and the personal consumption expenditures (PCE) price index on Friday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.39% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.6%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.31%.Here are the top stocks making the biggest moves in Wednesday’s midday trade:<a href="https://stocktwits.com/symbol/LAC">Lithium Americas Corp. (LAC)</a>Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lithium-americas-stock-surge-captures-wall-street-attention-here-is-why/chD1GtUR33g">confirmed</a> that it is in talks with the U.S. Department of Energy and its joint venture partner General Motors Co. (GM) in the Thacker Pass lithium project over the renegotiation of a $2.26 billion Energy Department loan.<a href="https://stocktwits.com/symbol/LAC">LAC stock</a> is up 101% year-to-date.<a href="https://stocktwits.com/symbol/BABA">Alibaba Group Holdings (BABA)</a>Alibaba’s U.S.-listed shares surged more than 9% in Wednesday’s afternoon session after the company announced plans to boost investment in artificial intelligence by over $53 billion.<a href="https://stocktwits.com/symbol/BABA">BABA stock</a> is up 110% year-to-date.<a href="https://stocktwits.com/symbol/QURE">uniQure NV (QURE)</a>uniQure shares soared more than 260% on Wednesday afternoon after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">said</a> that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is up 178% year-to-date.<a href="https://stocktwits.com/symbol/IREN">IREN (IREN)</a>IREN shares surged over 16% on Wednesday afternoon following an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iren-stock-surged-15-percent-today-here-is-a-price-target-update/chD1drjR33t">announcement</a> by the company that it has doubled its AI Cloud capacity to a total of 23,000 GPUs (graphic processing units), supporting the company’s goal of achieving more than $500 million in annualized AI Cloud revenue by the first quarter of 2026.<a href="https://stocktwits.com/symbol/IREN">IREN stock</a> is up 393% year-to-date.<a href="https://stocktwits.com/symbol/CDTX">Cidara Therapeutics Inc. (CDTX)</a>Cidara shares gained over 21% in Wednesday’s afternoon trade after the company announced plans for a Phase 3 study for CD388, a non-vaccine preventative of seasonal influenza.<a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> is up 232% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/scott-bessent-surprised-by-strength-of-fed-chair-candidates/chD1cDJR33N">Scott Bessent Says He’s Surprised By Strength Of Fed Chair Candidates: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today

Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the firm confirmed that it is in talks with the Energy Department and GM over the $2.6 billion Thacker Pass project loan.

Equity

Cidara Therapeutics (CDTX) Upgraded to Buy: Here's What You Should Know

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?

Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Shares of Cidada Therapeutics doubled in value on Monday&nbsp;and jumped in after-hours trading as the biotech firm released positive results from a trial of its flu drug candidate,&nbsp;managing to offset pressure from plans for a $250 million share offering.Cidara will offer all shares, and underwriters will receive a 30-day option to buy up to 15% more shares.&nbsp;J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor are leading the deal.&nbsp;The disclosure&nbsp;follows a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cidara-therapeutics-market-cap-doubles-after-investigational-drug-shows-positive-results-in-preventing-influenza/chm5alCRRdd">mid-stage trial of CD388</a>, a long-acting antiviral being developed to protect against seasonal flu.&nbsp;In the trial, which enrolled healthy adults between 18 and 64 who had not been given flu vaccines, CD388 was administered in three single doses.Each dose showed statistically meaningful protection against the flu over a 24-week period, with the highest dose offering up to 76% protection.Cidara said the treatment was well tolerated at all tested levels, with no significant safety concerns.Based on the outcome, the company has formally asked the U.S. Food and Drug Administration (USFDA) to hold a meeting to review the findings and discuss next steps for a Phase 3 trial.CD388 is being developed using Cidara’s Cloudbreak platform and is designed to offer once-per-season protection against both influenza A and B viruses.&nbsp;The company expects to share further results at upcoming medical meetings.Following the update, H.C. Wainwright raised its price target on Cidara Therapeutics to $53 from $41, citing strong mid-stage trial results for CD388 and boosting its success probability to 75%.&nbsp;RBC Capital also lifted its target to $75 from $35, calling CD388 a potentially groundbreaking long-acting flu preventative.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 31,400% surge in 24-hour message volume.One user said Cidara’s rally was unusual for a company announcing a large capital raise, warning short sellers to be cautious.&nbsp;<stembedurl>https://stocktwits.com/Stmkr/message/618765398</stembedurl>Another user noted that no price had been set for the offering yet and said they planned to watch how the situation unfolds in the next session.<stembedurl>https://stocktwits.com/Lstreak/message/618734296</stembedurl>The stock has risen 64.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering

The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor.

Cidara Therapeutics, Inc. (CDTX) on Monday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cidara.com/news/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating-cd388-a-non-vaccine-preventative-of-seasonal-influenza/">announced</a> positive results from its mid-stage trial evaluating CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64.Cidara’s shares nearly doubled in value as of Monday afternoon.Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said. The doses were administered at the beginning of the flu season.CD388 was well-tolerated at all doses with no unexpected dose-limiting treatment-emergent adverse events observed, the company added.CD388 is not a vaccine. Instead, it is an investigational drug-Fc conjugate (DFC), or low molecular weight biologics, which are designed to function as long-acting small molecule inhibitors.As it is not a vaccine, its activity is not reliant on an immune response and, thereby, is expected to be efficacious in individuals regardless of immune status.CEO Jeffrey Stein stated that the trial results reinforce the company’s confidence in the potential of CD388 to provide seasonal protection against influenza A and B.Cidara stated that it has submitted a request to the U.S. Food and Drug Administration to review the results of the mid-stage trial and discuss the design and timing of a late-stage trial.Following the update, H.C. Wainwright raised its price target on Cidara to $53 from $41 and kept a ‘Buy’ rating on the shares.The new price target implies a 152% upside to the stock’s closing price on Friday.The analyst further increased the probability of success for CD388 to 75% from 60% based on the positive mid-stage trial data.RBC Capital also raised the firm's price target on Cidara Therapeutics to $75 from $35 while keeping an 'Outperform' rating on the shares. The results from the recent study position CD388 as a potential groundbreaking, long-acting flu preventative that could combine and enhance the benefits of existing vaccines and prophylactics, it said.On Stocktwits, retail sentiment around Cidara soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_1_07_39_PM_png_569e678349.webp" alt="CDTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on June 23, 2025 | Source: Stocktwits" width="627" height="67"><figcaption>CDTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user highlighted the company’s debt-free status and strong cash position.<stembedurl>https://stocktwits.com/Vulcooo/message/618688709</stembedurl>Cidara ended the first quarter with $174.5 million in cash, cash equivalents, and restricted cash.<a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> is up by about 56% this year and by about 272% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/compass-pathways-stock-slumps-after-positive-late-stage-trial-results-from-psychedelic-drug-underwhelm-analysts/chm59LwRRdc">Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial

Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said.

Cidara Therapeutics: A Strong Buy on Promising Trials and Strategic Milestones

Cidara Therapeutics (CDTX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer...

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX CDTX INVESTOR NOTICE: ROSEN, TOP...

CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation CDTX

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from...

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonstrates potent efficacy in colorectal cancer...

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CDTX
Cidara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CDTX News

CDTX Cidara Therapeutics Inc